Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB105 in Advanced Solid Tumors
NCT07380386Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SKB105 in solid tumor, sponsored by Kelun-Biotech. Primary endpoints: Dose-Limiting Toxicity at 21 days and Objective Response Rate up to 3 years. Started Mar 2026; status: recruiting.
02
Drugs
SKB105
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07380386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07380386.